A 26-week, multinational, multi-centre, open-labelled, two-arm, parallel, randomised, treat-to-target trial comparing efficacy and safety of soluble insulin analogue combination (SIAC) once daily plus meal-time insulin aspart for the remaining meals vs. basal-bolus treatment with insulin detemir plus meal-time insulin aspart in subjects with type 1 diabetes
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin aspart; Insulin detemir
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BOOST
- Sponsors Novo Nordisk
- 28 Aug 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
- 28 Aug 2012 Results published in Diabetes Care.
- 08 Dec 2011 Results presented at the 21st World Diabetes Congress.